D. Boral Capital Reiterates Buy Rating for ImmunityBio (NASDAQ:IBRX)

ImmunityBio (NASDAQ:IBRX)‘s stock had its “buy” rating reaffirmed by equities researchers at D. Boral Capital in a research note issued to investors on Thursday,Benzinga reports. They presently have a $24.00 price target on the stock.

A number of other research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $8.00 price target on shares of ImmunityBio in a research report on Wednesday, September 10th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a research note on Wednesday, November 5th. Four analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $10.75.

ImmunityBio Stock Up 4.0%

IBRX opened at $2.08 on Thursday. The business’s fifty day simple moving average is $2.45 and its 200 day simple moving average is $2.56. ImmunityBio has a 52 week low of $1.83 and a 52 week high of $5.43. The stock has a market cap of $2.05 billion, a PE ratio of -5.07 and a beta of 0.29.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.10) by $0.03. The firm had revenue of $32.06 million for the quarter, compared to the consensus estimate of $31.88 million. As a group, equities analysts anticipate that ImmunityBio will post -0.92 earnings per share for the current year.

Hedge Funds Weigh In On ImmunityBio

Several hedge funds have recently made changes to their positions in IBRX. Slow Capital Inc. purchased a new position in shares of ImmunityBio during the 3rd quarter worth approximately $25,000. Truist Financial Corp purchased a new position in shares of ImmunityBio in the 3rd quarter valued at approximately $27,000. Diversify Advisory Services LLC bought a new stake in shares of ImmunityBio during the second quarter valued at approximately $27,000. Financial Enhancement Group LLC purchased a new stake in ImmunityBio in the second quarter worth $28,000. Finally, Summit X LLC bought a new position in ImmunityBio in the second quarter worth $28,000. 8.58% of the stock is owned by hedge funds and other institutional investors.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.